MindMed Just Dosed Their First Patient in LSD Clinical Trial for Anxiety
MindMed has announced the start of its Phase 3 Voyage study for MM120, a treatment targeting generalized anxiety disorder (GAD). They have officially dosed their first participant This study is the latest step in the company’s mission to bring new, innovative treatments to people struggling with anxiety. It follows encouraging results from earlier trials, specifically a Phase 2b study that showed MM120’s potential to significantly reduce anxiety symptoms.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
A Critical Step for Treatment of GAD
GAD affects millions of people, yet treatment options have remained limited. Current medications are often slow to work and can have side effects that patients find hard to tolerate. MM120, a pharmaceutically optimized form of LSD, has shown promise for providing faster relief. The Phase 3 study is set to involve 200 participants and will evaluate the drug’s effectiveness over a 12-week period. The primary goal is to assess improvements in anxiety using the Hamilton Anxiety Rating Scale, a key measure in anxiety research.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
A breakdown of the progress of MindMed’s MM120 clinical trial, from inception to the current Phase 3 stage:
| Stage | Timeline | Key Developments |
|---|---|---|
| Preclinical Research | Early development phase | Initial research into MM120 (LSD formulation) to assess its safety and efficacy for treating anxiety. |
| Phase 1 (Safety and Dosage) | Completed (2020) | First human trials to assess the safety, tolerability, and pharmacokinetics of MM120. |
| Phase 2a (Exploratory Study) | Completed (2021) | Small-scale trial to evaluate safety and potential effectiveness of MM120 in patients with anxiety disorders. |
| Phase 2b (Efficacy Study) | Completed (2023) | Expanded study showing significant reductions in anxiety symptoms, providing evidence for MM120’s efficacy. |
| Phase 3 (Voyage Study) | Current (2024-Present) | Large-scale trial with 200 participants to further assess the efficacy and safety of MM120 in treating GAD. |
The Study Design and Its Potential Impact
This study has two phases: a double-blind period followed by a 40-week open-label extension. The first phase will focus on assessing MM120’s efficacy, while the second phase will provide ongoing treatment to eligible participants. If the results align with previous studies, MM120 could represent a major breakthrough for GAD sufferers. Which could ultimately offer a new option in a market that has seen little innovation in the past decade.
MindMed’s forward-thinking approach might not only change the landscape of anxiety treatment but also influence broader psychiatric care.
The results from the Phase 3 study are expected to be available in 2026. But the potential for positive outcomes has already sparked considerable interest within the medical community.
